Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) saw a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 800 shares, a drop of 20.0% from the October 31st total of 1,000 shares. Based on an average daily volume of 3,000 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Investors Weigh In On Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans purchased a new stake in Tema Oncology ETF (NASDAQ:CANC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned about 19.01% of Tema Oncology ETF at the end of the most recent reporting period.

Tema Oncology ETF Stock Up 0.5 %

NASDAQ:CANC traded up $0.14 during mid-day trading on Friday, reaching $27.82. 171 shares of the stock were exchanged, compared to its average volume of 6,595. The stock has a market capitalization of $48.41 million, a P/E ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a 1 year low of $23.73 and a 1 year high of $30.11. The company has a 50 day simple moving average of $27.86 and a 200-day simple moving average of $28.12.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.